Designing Next-Generation Cardiometabolic Outcome Trials for Obesity Medicines - PubMed
14 hours ago
- #obesity
- #cardiovascular outcomes trial
- #GLP-1 receptor agonist
- Obesity is a global pandemic with significant public health impacts, increasing risks for type 2 diabetes, hypertension, chronic kidney disease, and cardiovascular diseases.
- Recent trials using GLP-1 receptor agonists in individuals with obesity have shown cardiovascular benefits, unlike earlier weight-loss strategies.
- Multiple cardiovascular outcome trials (CVOTs) for novel GLP-1 receptor agonists and other investigational products are currently planned or underway.
- The commentary discusses regulatory aspects and study design considerations for CVOTs targeting obesity medications, proposing five principles for next-generation cardio-kidney-metabolic outcome trials.
- Key topics include the evolution of CVOT design, the role of GLP-1 receptor agonists, and the future of obesity treatment trials.